## [Reporting and transparency hub](/investors/reporting-and-transparency-hub "Reporting and transparency hub") On this page, you can find our annual reporting documents and other disclosures, as well as many of our internal policies, codes, guidelines and commitments. ## Quick links [Annual Report 2025](#annual-report-form-20f) [US Securities & Exchange Commission Form 20-F 2025](#annual-report-form-20f) [Report on Nonfinancial Matters 2025​](#novartis-in-society-integrated-report) [Other reporting documents](#other-reporting-documents) [ESG index](#esg-index) [Reporting archive](#reporting-archive) [Investor relations](#investor-relations) [Policies and positions](#policies-and-positions) [Other disclosures](#other-disclosures) --- ## Annual reporting suite Access and download our annual regulatory filings and other reporting documents. ![Business people walking on the Novartis Basel campus](/sites/novartis_com/files/styles/crop_freeform/public/2026-02/business-people-walking-on-novartis-basel-campus-banner.jpg.webp?itok=SGpMcZjg "Business people walking on the Novartis Basel campus") ### Annual Report 2025 and US Securities & Exchange Commission Form 20-F 2025 These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerland and the Securities and Exchange Commission in the US. Novartis shareholders may receive a hard copy of either of these documents, each of which contains our complete audited financial statements, free of charge, upon request. [Annual Report 2025 (PDF 3.1 MB)](/sites/novartis_com/files/novartis-annual-report-2025.pdf "novartis-annual-report-2025.pdf") | [Form 20-F 2025 (PDF 3.1 MB)](/sites/novartis_com/files/novartis-20-f-2025.pdf "novartis-20-f-2025.pdf") ### Report on Nonfinancial Matters 2025 This report covers information on nonfinancial matters deemed material and in scope of our reporting obligations under the Swiss Code of Obligations (SCO), as well as our due diligence and reporting obligations in relation to child labor under the SCO.​ It includes our Human Rights Statement addressing specific jurisdictional requirements for disclosure on modern slavery, decent work, forced labor and child labor.​ [Download the report (PDF 1.0 MB)](/sites/novartis_com/files/novartis-report-nonfinancial-matters-2025.pdf "novartis-report-nonfinancial-matters-2025.pdf") | [HTML (ZIP 0.9 MB)](/sites/novartis_com/files/nvs-tcfd-2025-12-31.zip) You can order the publications [here](/news/stay-up-to-date). ### Other reporting documents **Update on Public Commitments 2025** Outlines the progress made toward our social impact and sustainability targets and aspirations. [Download the Update (PDF 0.3 MB)](/sites/novartis_com/files/novartis-update-public-commitments-2025.pdf "novartis-update-public-commitments-2025.pdf") **ESG Data Summary 2025** Nonfinancial performance metrics in the Report on Nonfinancial Matters 2025, the Update on Public Commitments 2025 and data supporting information on our website. [Download the Summary (PDF 0.3 MB)](/sites/novartis_com/files/novartis-esg-data-summary-2025.pdf "novartis-esg-data-summary-2025.pdf") | [Spreadsheet (ZIP 32 KB)](/sites/novartis_com/files/novartis-esg-data-summary-2025.zip) **Sustainability Accounting Standards Board (SASB) index** A summary of our alignment with SASB's Biotechnology & Pharmaceuticals Sustainability Accounting Standard across different disclosures. [Download the SASB index (PDF 0.2 MB)](/sites/novartis_com/files/novartis-sasb-index-2025.pdf "novartis-sasb-index-2025.pdf") --- ## ESG index Our ESG index provides an overview of various topics of interest to investors, analysts, and other stakeholders. We aim to report comprehensively and transparently on our actions, objectives and progress. The ESG index also shows where disclosures can be found across our publications and website. [Learn more](/esg/index "Novartis ESG index") ## Reporting archive Access our annual reports and other disclosures from prior years. [Learn more](/investors/reporting-and-transparency-hub/reporting-archive "Reporting archive") ## Investor relations We aim for sustainable performance over time to benefit patients, employees, shareholders and society. [ ### Quarterly results Quarterly financial performance and social impact and sustainability newsletter. ](/investors/financial-data/quarterly-results) [ ### Annual results Media releases, webcasts and presentations on our annual results. ](/investors/financial-data/annual-results) [ ### Event calendar View recent presentations and learn more about upcoming events. ](/investors/event-calendar) [ ### Shareholder information Updates about general meetings and other frequently asked questions. ](/investors/shareholder-information) ## Policies and positions As part of our ongoing commitment to transparency, we publish our positions on various issues affecting our business. We are also transparent about our values and behaviors, our approach to managing ethical decisions, and the standards we expect of our suppliers. This section includes many of the policies, codes, guidelines and commitments that govern the company's activities. - [Positions](#tabpositions-220171) - [Codes, Policies and Guidelines](#tabcodes-policies-and-guidelines-220111) ## [Positions](/node/639291 "Positions") Access - [Access to medicines (PDF 0.2 MB)](/sites/novartis_com/files/access-to-medicines.pdf "access-to-healthcare-perspective.pdf") R&D - [Animal research (PDF 0.2 MB)](/sites/novartis_com/files/animal-research.pdf "animal-research.pdf") - [Clinical study transparency (PDF 0.2 MB)](/sites/novartis_com/files/clinical-trial-data-transparency.pdf "clinical-trial-data-transparency.pdf") - [Medicines for Patients with Rare Diseases (PDF 0.2 MB)](/sites/novartis_com/files/medicines-for-patients-with-rare-diseases.pdf "medicines-for-patients-with-rare-diseases.pdf") - [Post-trial Access (PDF 0.1 MB)](/sites/novartis_com/files/novartis-position-on-post-trial-access.pdf "novartis-position-on-post-trial-access.pdf") - [Novartis Position on Access to Unauthorized Novartis Products through Managed Access Programs (MAPs) (PDF 0.2 MB)](/sites/novartis_com/files/novartis-position-unauthorized-products-access.pdf "novartis-position-unauthorized-products-access.pdf") - [Responsible Clinical Trials (PDF 0.1 MB)](/sites/novartis_com/files/novartis-position-on-responsible-clinical-trials.pdf "novartis-position-on-responsible-clinical-trials.pdf") - [Novartis Commitment to Diversity in Clinical Trials (PDF 0.2 MB)](/sites/novartis_com/files/commitment-for-diversity-in-clinical-trials.pdf "commitment-for-diversity-in-clinical-trials.pdf") - [Novartis Position on Investigator Initiated Trials (IITs) and Investigator Initiated Research (IIRs) (PDF 0.2 MB)](/sites/novartis_com/files/novartis-investigator-initiated-trials.pdf "novartis-investigator-initiated-trials.pdf") - [Position on Scientific Publications (PDF 0.2 MB)](/sites/novartis_com/files/position-on-scientific-publications.pdf "novartis-publication-guidelines-posting.pdf") Quality and safety of medicines - [Falsified Medical Products (PDF 0.3 MB)](/sites/novartis_com/files/novartis-position-on-falsified-medical-products.pdf "novartis-position-on-falsified-medical-products.pdf") Intellectual property - [Intellectual Property (PDF 0.3 MB)](/sites/novartis_com/files/novartis-intellectual-property-position.pdf "novartis-intellectual-property-position.pdf") - [Regulatory data protection (PDF 0.3 MB)](/sites/novartis_com/files/regulatory-data-protection.pdf "regulatory-data-protection.pdf") Ethics - [Novartis Position on Collaborating with Patient Organizations (PDF 0.2 MB)](/sites/novartis_com/files/novartis-position-on-collaborating-with-patient-organizations.pdf "novartis-position-on-collaborating-with-patient-organizations.pdf") Environment - [Pharmaceuticals in the environment (PDF 0.2 MB)](/sites/novartis_com/files/pharmaceuticals-environment.pdf "pharmaceuticals-environment.pdf") Taxation - [Novartis Tax Policy Statement (PDF 0.2 MB)](/sites/novartis_com/files/tax-policy-statement.pdf "tax-policy-statement.pdf") - [Print](/node/639291/printable/print) - [PDF](/node/639291/printable/pdf) ## [Codes, Policies and Guidelines](/node/639286 "Codes, Policies and Guidelines") Ethics and compliance - [Novartis Code of Ethics (PDF 4.1 MB)](/sites/novartis_com/files/code-of-ethics-english.pdf "code-of-ethics-english.pdf") - [Doing Business Ethically Policy (PDF 0.4 MB)](/sites/novartis_com/files/doing-business-ethically-policy.pdf "doing-business-ethically-policy.pdf") - [Novartis Conflicts of Interest Policy (PDF 0.3 MB)](/sites/novartis_com/files/conflicts-of-interest-policy.pdf "conflict-of-interest-guideline.pdf") Health, safety and environment - [Novartis Global Health, Safety and Environment Policy (PDF 0.3 MB)](/sites/novartis_com/files/health-safety-environment-policy.pdf "health-safety-environment-policy.pdf") Human rights - [People & Organization Commitment Statement (PDF 0.3 MB)](/sites/novartis_com/files/people-organization-commitment-statement.pdf "people-organization-commitment-statement.pdf") - [Non-Discrimination, Non-Harassment and Civility Policy (PDF 0.3 MB)](/sites/novartis_com/files/novartis-global-non-discrimination-non-harassment-and-non-retaliation-guideline.pdf "novartis-global-non-discrimination-non-harassment-and-non-retaliation-guideline.pdf") - [Non-Retaliation Policy (PDF 0.3 MB)](/sites/novartis_com/files/novartis-non-retaliation-policy.pdf "novartis-non-retaliation-policy.pdf") - [Human Rights Commitment Statement (PDF 6.9 MB)](/sites/novartis_com/files/novartis-human-rights-commitment-statement.pdf "novartis-human-rights-commitment-statement.pdf") Privacy - [Novartis Privacy Hub](/privacy "Novartis Privacy Hub") Research - [Novartis Animal Welfare Policy (PDF 0.3 MB)](/sites/novartis_com/files/novartis-global-animal-welfare-policy.pdf "novartis-global-animal-welfare-policy.pdf") Suppliers and third parties - [Novartis Third Party Code v. 1.0 (PDF 0.6 MB)](/sites/novartis_com/files/novartis-third-party-code.pdf "novartis-third-party-code.pdf")\* - [Novartis Third Party Code v. 2.0 (PDF 0.3 MB)](/sites/novartis_com/files/novartis-third-party-code-v-2.pdf "novartis-third-party-code-v-2.pdf")\*\* - [Novartis Third Party Code v. 3.0 (PDF 0.4 MB)](/sites/novartis_com/files/novartis-third-party-code-v-3.pdf "novartis-third-party-code-v-3.pdf")\*\*\* - [Novartis Third Party Code v. 4.0 (PDF 0.5 MB)](/sites/novartis_com/files/novartis-third-party-code-v-4.pdf "novartis-third-party-code-v-3.pdf")\*\*\*\* - [Novartis Minimum Information Security Controls for Suppliers (PDF 0.5 MB)](/sites/novartis_com/files/novartis-minimum-information-security-controls.pdf "novartis-minimum-information-security-controls.pdf") --- \* v1.0 remains valid for contracts entered into up to October 31, 2020 unless the contract stipulates that the most up-to-date TPC version is to be adhered to. \*\* v2.0 remains valid for contracts entered into up to December 31, 2022 unless the contract stipulates that the most up-to-date TPC version is to be adhered to. \*\*\* v3.0 remains valid for contracts entered into up to June 30, 2025 unless the contract stipulates that the most up-to-date TPC version is to be adhered to. \*\*\*\* v4.0 is valid for contracts entered into as from July 1, 2025 - [Print](/node/639286/printable/print) - [PDF](/node/639286/printable/pdf) ## Other disclosures Our commitment to being open and clearly disclosing what we do extends to our relationships with external stakeholders such as patients and patient organizations, healthcare professionals, policymakers and others. [ ### Social Impact & Sustainability targets Discover our Social Impact & Sustainability targets and aspirations that bring our strategy to life. ](/investors/reporting-and-transparency-hub/social-impact-and-sustainability-targets) [ ### ESG rating performance Ratings by Access to Medicine Index, CDP, MSCI, Sustainalytics and ISS ESG. ](/investors/reporting-and-transparency-hub/esg-rating-performance) [ ### Public policy We are transparent about our approach to engaging in public policy debates affecting our business. ](/investors/reporting-and-transparency-hub/public-policy) [ ### Patient organization funding We work with groups that advocate for patients and disclose these relationships. ](/investors/reporting-and-transparency-hub/patient-organization-funding) [ ### Clinical trials transparency Providing information on clinical trials and their results serves everyone including study participants, patients and healthcare providers. ](/clinicaltrials/transparency) [ ### Payments to healthcare professionals We publish payments to healthcare professionals and organizations in line with local laws or regulations. ](/healthcare-professionals/payments-healthcare-professionals) [ ### Animal research Animal research is governed by our animal welfare policy. ](/investors/reporting-and-transparency-hub/animal-research) div.table-content .text-formatted.field .link.button-border, .text-formatted.field a.button-border{ margin-right: 10px; }